Investigational drug · Phase 2
TT-10
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "TT-10"
First trial start
2023
Jun 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TT-10", any sponsor or status.
Conditions studied
As listed on its trial records.
- Renal Cell Cancer
- Castrate Resistant Prostate Cancer
- Non Small Cell Lung Cancer
- Pleural Mesothelioma Malignant
Approved drugs for the same conditions: Small cell lung cancer · Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "TT-10" as an intervention, largest first.
PfizerPfizer (PFE)
NCT01962207 · 243 participants · Start Oct 2013 · Primary completion Dec 2017
Drug: Meningococcal vaccine GSK134612 · For: Infections, Meningococcal
Sites: Espoo, Finland; Helsinki, Finland; Jarvenpaa, Finland · 9 sites in all
- Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain InjuryPivotal-lookingCompleted
Claudia Sue RobertsonAcademic, hospital or other
NCT00313716 · 200 participants · Start Apr 2006 · Primary completion Mar 2013
Drug: recombinant human erythropoietin, rhEpo · For: Anemia; Traumatic Brain Injury
Sites: Houston, Texas
Portage BiotechIndustry
NCT04969315 · 35 participants (planned) · Start Jun 23, 2023 · Primary completion Dec 1, 2028
Drug: TT-10; TT-4 · For: Renal Cell Cancer; Castrate Resistant Prostate Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Los Angeles, California; Houston, Texas
Texas Tech University Health Sciences CenterAcademic, hospital or other
NCT03708354 · 0 participants · Start Apr 15, 2019 · Primary completion Dec 31, 2022
Drug: placebo softgel; DeltaGold® Tocotrienol 70% · For: Dynapenia; Postmenopausal Women
Sites: Lubbock, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case-control study.
Naber WC, Brandt RB, Leon Morales-Grooters M, et al. · Headache 2026
- Moderate altitude-mimicking CO-induced inhibition of hemoglobin oxygen binding decreased middle-distance swimming speed in male national-level swimmers.
Venckunas T, Achramavicius J, Westerblad H, et al. · Eur J Appl Physiol 2026
- A Novel Conditioning Regimen Incorporating Low-Dose Cyclophosphamide and Thiotepa for Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients with Severe Aplastic Anemia at High Risk of Cardiotoxicity.
Zhang F, Suo P, Hu GH, et al. · Transplant Cell Ther 2026
- Treatment with Hippo/YAP pathway modulators partially improves testicular and sperm phenotypes following cisplatin stimulation.
Pakpahan C, Faizah Z, Amanda B, et al. · Arch Ital Urol Androl 2026
- Macrophage-Specific Loss of Stearoyl-CoA Desaturase 1 Promotes Colon Cancer by Enhancing M2 TAM Polarization.
You Q, Du J, Wei Z, et al. · Cancer Sci 2026
- Physiological determinants and energy system contribution in short- and middle-distance cycling performance.
Gjerløw LE, Støa EM, Helgerud J, et al. · Eur J Appl Physiol 2026
Also in development for Renal Cell Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.